ETS Translocation Variant 5 Negatively Modulates Innate Immunity to Facilitate Epstein-Barr Virus Reactivation

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Epstein-Barr virus (EBV) infection is widespread, with latent and lytic phases.
• Innate immunity typically restricts EBV replication during lytic reactivation.
• Understanding EBV's immune evasion strategies is crucial for disease management.

Purpose of the Study:

• To identify host factors regulating innate immune responses during EBV lytic reactivation.
• To elucidate the role of ETS translocation variant 5 (ETV5) in EBV reactivation and immune suppression.

Main Methods:

• Investigated ETV5 expression during EBV latent and lytic phases.
• Assessed the impact of ETV5 overexpression and knockdown on EBV lytic replication.
• Analyzed the effect of ETV5 on innate immune signaling pathways, including IRF3 and IFNB1.

Main Results:

• ETV5 expression is upregulated during EBV latent infection and further increased during lytic reactivation.
• ETV5 overexpression significantly enhances EBV lytic replication.
• ETV5 suppresses the activation of TANK-binding kinase 1 and IRF3, inhibiting IFNB1 and ISG transcription.
• ETV5 knockdown reverses the immune suppression, and its effects can be counteracted by innate immunity pathway inhibitors.

Conclusions:

• ETV5 acts as a critical accelerator of EBV reactivation by suppressing innate immune responses.
• ETV5 facilitates EBV immune evasion, promoting viral replication.
• ETV5 represents a novel therapeutic target for controlling EBV reactivation and associated diseases.